期刊
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
卷 28, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.nano.2020.102207
关键词
Ovarian cancer; Exosomes; Nanovesicles; miRNAs; Biomarkers
资金
- King Saud University (K.S.A), Riyadh
- Lions Medical Research Foundation
- UQ-Ochsner Seed Fund for Collaborative Research, The University of Queensland
- Faculty of MedicineM + BS Emerging LeadersMedical Research Grant
- Fondo Nacional de Desarrollo Cientifico y Tecnologico [FONDECYT 1170809]
- Ovarian Cancer Research Foundation
Carboplatin, administered as a single drug or in combination with paclitaxel, is the standard chemotherapy treatment for patients with ovarian cancer (OVCA). Recent evidence suggests that miRNAs associated with small extracellular vesicles (sEVs) participate in the development of chemoresistance. We studied the effect of carboplatin in a heterogeneity population of OVCA cells and their derived sEVs to identify mechanisms associated with chemoresistance. sEVs were quantified using an engineered superparamagnetic material, gold-loaded ferric oxide nanotubes and a screen-printed electrode. miR-21-3p, miR-21-5p, and miR-891-5p are enriched in sEVs, and they contribute to carboplatin resistance in OVCA. Using a quantitative MS/MS, miR-21-5p activates glycolysis and increases the expression of ATP-binding cassette family and a detoxification enzyme. miR-21-3p and miR-891-5p increase the expression of proteins involved in DNA repair mechanisms. Interestingly, the levels of miR-8915p within sEVs are significantly higher in patients at risk of ovarian cancer relapse. Identification of miRNAs in sEVs also provides the opportunity to track them in biological fluids to potentially determine patient response to chemotherapy. (C) 2020 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据